Treatment and progress of cutaneous neurofibroma

• Published in: Zhongguo xiu fu chong jian wai ke za zhi Vol. 36; no. 9; p. 1064
• Main Authors: Zhu, Beiyao, Wei, Chengjiang, Wang, Wei, Gu, Bin, Li, Qingfeng, Wang, Zhichao
• Format: Journal Article
• Language: Chinese
• Published: China 15-09-2022
• Subjects: Carbon Dioxide; Humans; Mitogen-Activated Protein Kinase Kinases; Neurofibroma - metabolism; Neurofibroma - pathology; Neurofibroma - therapy; Protein-Tyrosine Kinases; Quality of Life; Skin Neoplasms - pathology; Skin Neoplasms - therapy; TOR Serine-Threonine Kinases; cutaneous neurofibroma; treatment; Neurofibromatosis type 1; research progress
• ISSN: 1002-1892
• DOI: 10.7507/1002-1892.202205072

To summarize current widely-used therapies for cutaneous neurofibroma (cNF) and related research progress.
Based on extensive investigation of domestic and foreign research, the existing treatment of cNF, including the indications, effectiveness and trials of targeted drugs were reviewed.
cNF is a hallmark feature of neurofibromatosis type 1 and has a dramatic negative impact on patient appearance and quality of life. At present, there is no standard management of cNF. Invasive treatment is a commonly-used treatment. Surgical removal gives excellent cosmetic results, but it is difficult for multiple tumors; CO
laser ablation, laser photocoagulation, electro-drying, and radiofrequency ablation are effective in treating lots of cNF at one time. Although fast and effective, these therapies can lead to depigmentation, hyperpigmentation, or extensive scarring. There is no targeted drug approval for cNF, and a series of studies have been carried out on the Ras-MEK pathway, Ras-mTOR pathway, receptor tyrosine kinase